Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Revenue (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Revenue data on record, last reported at $5.1 million in Q4 2025.

  • For Q4 2025, Revenue rose 258.23% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $35.6 million, up 370.22%, while the annual FY2025 figure was $35.6 million, 370.22% up from the prior year.
  • Revenue reached $5.1 million in Q4 2025 per VRCA's latest filing, down from $14.3 million in the prior quarter.
  • Across five years, Revenue topped out at $14.3 million in Q3 2025 and bottomed at -$3.2 million in Q4 2024.
  • Average Revenue over 5 years is $4.1 million, with a median of $2.9 million recorded in 2023.
  • The widest YoY moves for Revenue: up 10240.54% in 2024, down 261.87% in 2024.
  • A 5-year view of Revenue shows it stood at $12.0 million in 2021, then crashed by 99.43% to $68000.0 in 2022, then soared by 2823.53% to $2.0 million in 2023, then plummeted by 261.87% to -$3.2 million in 2024, then soared by 258.23% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $5.1 million in Q4 2025, $14.3 million in Q3 2025, and $12.7 million in Q2 2025.